Real-life use of cabozantinib as front-line therapy in metastatic renal cell carcinoma: The CabFRONT (Meet-URO 24) study. This is an ASCO Meeting Abstract from the 2023 ASCO Annual Meeting I. This ...
A new study published in the Journal of American Heart Association showed that in patients with stable coronary artery ...
On Tuesday, Coya Therapeutics, Inc. (NASDAQ:COYA) released results from the placebo-controlled Phase 2 trial of LD IL-2 in patients with mild to moderate Alzheimer’s Disease. The data was shared at ...
A phase I study showed activity with WTX-124, a novel interleukin-2 (IL-2) prodrug, in patients with locally advanced or metastatic solid cancers whose tumors progressed after checkpoint inhibition.
Accumulation of lymphocytes following adoptive transfer of allogeneic T lymphocytes equipped with an HLA-A2 restricted, MART-1 reactive T Cell Receptor No significant financial relationships to ...
BARCELONA, Spain--(BUSINESS WIRE)--Almirall S.A. (BME: ALM), a global pharmaceutical company focused on medical dermatology, today announced the initiation of the phase I study evaluating the safety, ...
The results of the MIROCALS randomized clinical trial have shown that adding low-dose interleukin-2 (IL2LD) to standard treatment for amyotrophic lateral sclerosis slowed functional decline and ...
BIRMINGHAM, Ala. – The immune system has a biological telecommunications system — small proteins known as interleukins that send signals among the leukocyte white blood cells to control their defense ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results